Performance of the FebriDx Rapid Point-of-Care Test for Differentiating Bacterial and Viral Respiratory Tract Infections in Patients with a Suspected Respiratory Tract Infection in the Emergency Department

FebriDx is a rapid point-of-care test combining qualitative measurements of C-reactive protein (CRP) and Myxovirus Resistance Protein A (MxA) using a disposable test device to detect and differentiate acute bacterial from viral respiratory tract infections. The goal of this study was to investigate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2023-12, Vol.13 (1), p.163
Main Authors: Tong-Minh, Kirby, Daenen, Katrijn, Endeman, Henrik, Ramakers, Christian, Gommers, Diederik, van Gorp, Eric, van der Does, Yuri
Format: Article
Language:English
Subjects:
Accuracy
Antibiotics
Bacterial infections
Biomarkers
Blood
Care and treatment
Comorbidity
COVID-19
Diagnosis
Emergency medical care
Emergency service
Hospitals
Immune system
Immunocompetence
Infections
Laboratories
Patients
Physicians
Polymerase chain reaction
Proteins
Respiratory tract diseases
Testing
Tumor necrosis factor-TNF
Viral infections
Vital signs
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:FebriDx is a rapid point-of-care test combining qualitative measurements of C-reactive protein (CRP) and Myxovirus Resistance Protein A (MxA) using a disposable test device to detect and differentiate acute bacterial from viral respiratory tract infections. The goal of this study was to investigate the diagnostic accuracy of FebriDx in patients with suspected respiratory tract infections in the emergency department (ED). This was an observational cohort study, performed in the ED of an academic hospital. Patients were included if they had a suspected infection. The primary outcome was the presence of a bacterial or viral infection, determined by clinical adjudication by an expert panel. The sensitivity, specificity, and positive and negative predictive value of FebriDx for the presence of bacterial versus non-bacterial infections, and viral versus non-viral infections were calculated. Between March 2019 and November 2020, 244 patients were included. A bacterial infection was present in 41%, viral infection was present in 24%, and 4% of the patients had both viral and bacterial pathogens. FebriDx demonstrated high sensitivity in the detection of bacterial infection (87%), high NPV (91%) to rule out bacterial infection, and high specificity (94%) for viral infection in patients with a suspected infection in the ED.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm13010163